PCWP Analysis
Overview
Cardiosense offers an FDA-cleared AI tool, PCWP Analysis Software, designed to noninvasively estimate pulmonary capillary wedge pressure (PCWP) using a wearable sensor called CardioTag™. This technology provides real-time, objective hemodynamic insights to help clinicians more precisely and proactively manage heart failure patients, potentially weeks before fluid buildup and symptoms arise. The solution aims to optimize medical therapy with quantitative, longitudinal hemodynamic history, eliminating guesswork with rapid, easy-to-use, and accurate PCWP readings at the point-of-care, in clinics, or at home. Cardiosense leverages wearable technology, signal processing, and deep learning to convert raw physiological data into clinical intelligence, addressing complex cardiovascular challenges and transforming heart failure management across the patient journey.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Noninvasive PCWP estimation
- Wearable CardioTagu2122 sensor
- Real-time hemodynamic insights
- Objective, quantitative PCWP readings
- Early detection of worsening heart failure
- Optimizes medical therapy
- Point-of-care, in-clinic, and at-home use
- FDA authorized Class II medical device
- AI platform for clinical intelligence
- Reduces heart failure hospitalizations
Use Cases
- ED assessment and triage for heart failure
- Inpatient management and discharge optimization
- Outpatient and at-home PCWP monitoring
- Optimizing guideline-directed medical therapy (GDMT)
- Early detection and intervention for heart failure decompensation
- Reducing heart failure hospitalizations
What Physicians Need to Know
The Cardiosense PCWP Analysis Software offers a noninvasive method to estimate PCWP, traditionally requiring invasive procedures. This can facilitate more frequent and proactive hemodynamic monitoring in eligible HFrEF patients (LVEF u226440%, NYHA Class II-IV symptoms) in various settings, including at the bedside, in clinic, or at home. The rapid availability of quantitative PCWP readings (in minutes) can aid in optimizing medical therapy and potentially preventing hospitalizations by allowing for earlier intervention before symptomatic decompensation. While promising for guiding individualized therapy adjustments, it's important to note that current authorization is specific to HFrEF, and outcome data demonstrating reduced hospitalization or improved quality of life are not yet available.
The PCWP Analysis Software integrates with the CardioTagu2122 wearable chest sensor. The broader CardioSense AI platform supports seamless integration with existing Electronic Medical Record (EMR) systems, including Epic, Cerner, and Allscripts, through HL7 FHIR standards and custom API endpoints. This suggests a potential for future integration of PCWP data into comprehensive patient records and workflows.
Details
| Category | Cardiology AI, Clinical Decision Support & Reference, Wearables & Remote Monitoring (RPM) |
| Pricing | Contact for pricing |
| Deployment | Cloud-based software with wearable sensor |
| Compliance | |
| BAA Available | Unknown |
| HIPAA Compliant | Unknown |
| FDA Status | Cleared AI-estimated |
| Integrations | |
| EHR | Not specified |
| Specialties | Cardiology, Critical Care, Hospital Medicine |
What the Web Says
Cardiosense's PCWP Analysis Software is a novel, AI-powered, noninvasive technology designed to estimate pulmonary capillary wedge pressure (PCWP) in adult heart failure patients with reduced ejection fraction (HFrEF), specifically those with LVEF u226440% and NYHA Functional Class II, III, or IV symptoms. This technology aims to provide an alternative to traditional invasive methods (catheterization or implanted devices) for measuring PCWP, which is a key indicator of fluid buildup in heart failure patients and often rises before symptoms appear. The software utilizes data collected from a small wearable chest sensor called CardioTag, which captures seismocardiogram (SCG), electrocardiogram (ECG), and photoplethysmogram (PPG) signals. The technology has received FDA De Novo classification, and studies have shown its accuracy to be comparable to implanted pressure sensors.
Overall: PositiveStrengths
- Non-invasive measurement of PCWP, avoiding invasive catheterization or implanted devices.
- Earlier detection of fluid buildup and worsening heart failure, enabling proactive management.
- Accuracy comparable to implanted pressure sensors.
- Empowers healthcare providers to make more informed and frequent individualized therapy adjustments.
- Potential to prevent hospitalizations, accelerate discharge, and improve quality of life for heart failure patients.
- FDA De Novo classification and Breakthrough Device Designation.
Limitations
- Regulatory indication is currently narrower, restricted to symptomatic HFrEF (LVEF u226440%) in NYHA class IIu2013IV adults.
- Claims of reduced hospitalization, faster discharge, and improved quality of life lack supporting patient-level outcomes data.
- Unresolved questions remain regarding performance across various patient characteristics (body habitus, rhythm status, comorbidity burden, decompensated vs. stable HF populations).
- Unclear if estimates maintain accuracy longitudinally.
- No clear outcome data on whether the use of this data changes outcomes when incorporated into care pathways.
- A proof-of-concept study involved a small sample size (20 patients).
Based on reviews from: Cardiosense (via Business Wire), HCPLive, Becker's ASC, G-MedTech, HIT Consultant, PubMed, tctmd.com, The Journal of Innovations in Cardiac Rhythm Management, Reddit
Last updated: 2026-09-30
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate PCWP Analysis
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for PCWP Analysis.
AI Diagnostics, PCCPs, and FDA Turnover (ft. Jay Vaishnav) u2013 5/28/26
TTKU
Frequently Asked Questions
Investors who backed PCWP Analysis
Funded through the company that built this tool.
